BGNE NASDAQ
BeiGene, Ltd.
1W: +1.3%
1M: -10.6%
3M: -21.2%
1Y: +4.0%
3Y: -29.5%
5Y: +10.6%
$184.71
Last traded 2025-01-02 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships0
As Filer
counterparties named
4
As Counterparty
mentioned by others
2022-10-19
Earliest Filing
2023-05-16
Latest Filing
Mentioned As Counterparty
4 mentionsOther companies that named BGNE in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| ZYME Zymeworks Inc. | partner | Existing partner holding an agreement with Zymeworks BC Inc. for Asia Pacific territories, referenced in the scope of th | 2023-05-16 | View |
| AMGN AMGEN INC | investor | Amgen amended Share Purchase Agreement to relinquish director appointment right and change accounting method for equity | 2023-01-31 | View |
| JAZZ Jazz Pharmaceuticals plc | partner | Company to which Zymeworks previously licensed certain Asia/Pacific territories | 2022-12-05 | View |
| ZYME Zymeworks Inc. | partner | Holds exclusive rights to commercialize zanidatamab in countries excluded from the Jazz agreement. | 2022-10-19 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR